Immutep Limited
We are preparing, please wait
Undervalued or Overvalued?
Unfortunately, this content is only accessible to registered users
Login to ContinueKey stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Market Cap
$322.58 M
Change
$0.06
EPS
-$0.27
P/E Growth
-9.89
Australia Square, Sydney, NSW 2000
Sector:
Industry:
Fiscal Year-end
June
Revenue
$3.84 M
Net Income
$-42,716,625
2023 Sales Growth
9.59%
Immutep Limited's CEO, Mr. Marc Voigt
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Price
P/E CURRENT
$2.29
Changes Percentage
P/E CURRENT
2.47%
Change
P/E CURRENT
$0.06
Year High
P/E CURRENT
$3.34
An income statement known as a profit and loss statement, is a financial report that summarizes a company's revenues, expenses, gains, and losses over a specific period. It provides insight into a company's operational efficiency and profitability, helping investors and stakeholders assess financial performance and make informed decisions.
The Financials Balance Sheet report provides a clear and concise visual summary of a company’s financial standing through interactive charts. This section highlights key components such as assets, liabilities, and equity, offering investors an at-a-glance understanding of the company's financial health. By showcasing these critical metrics in an easy-to-digest format, the report enables stakeholders to evaluate the company’s stability, operational efficiency, and capital structure, fostering more informed investment decisions.
The Financials Cash Flow report uses charts to provide a clear breakdown of a company’s cash flow across operating, investing, and financing activities. This visualization helps investors quickly assess how the company generates, spends, and manages cash, offering valuable insights into its liquidity and financial efficiency.
Market Benchmark Score
Market Score: Aggregate the average P/E ratio of all companies in the market.
Industry Score: Aggregate the average P/E ratio of all companies in the same industry.
ASSETS
$201.58 M
LIABILITIES
$12.06 M
DEBT Equity Ratio
0.00
Operating Cash Flow
$-34,821,229
The latest Technical Analysis Summary on Stocks.News offers insights into market trends using key Technical Indicators like RSI and MACD, alongside Moving Averages such as the 50-day and 200-day. The analysis identifies buy and sell signals through bullish or bearish crossovers, helping investors make informed trading decisions.
Today's price of Immutep Limited is $2.29 — it has increased by +2.47%
Yes, you can track Immutep Limited's financials in yearly and quarterly reports directly on Stocks.News.
Watch the Immutep Limited chart and read a more detailed Immutep Limited stock forecast to see what analysts suggest you do with its shares.
The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Immutep Limited stock ticker.
Like other stocks, IMMP shares are sold on stock exchanges such as NASDAQ The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.
Immutep Limited measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Immutep Limited’s financial statements.
